FDA approves Enhertu for gastric cancer subset

The FDA approved fam-trastuzumab deruxtecan-nxki for treatment of certain patients with gastric or gastroesophageal adenocarcinoma.The approval applies to use of the agent by adults with locally advanced or metastatic HER2-positive disease who received a prior trastuzumab (Herceptin, Genentech)-based regimen.Fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) is a novel antibody-drug conjugate with three components: a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino acid sequence as trastuzumab; a topoisomerase 1 inhibitor payload; and aRead More

Share on facebook
Share on twitter
Share on linkedin